Patient reported outcomes among treatment modalities for prostate cancer

被引:0
|
作者
Johnson, Matthew E. [1 ]
Zaorsky, Nicholas G. [1 ]
Martin, Jeffrey M. [1 ]
Ruth, Karen [2 ]
Greenberg, Richard E. [3 ]
Uzzo, Robert G. [3 ]
Hayes, Shelly B. [1 ]
Smaldone, Marc C. [3 ]
Kutikov, Alexander [3 ]
Viterbo, Rosalia [3 ]
Chen, David Y. T. [3 ]
Hallman, Mark A. [1 ]
Sobczak, Mark L. [1 ]
Horwitz, Eric M. [1 ]
机构
[1] Fox Chase Canc Ctr, Dept Radiat Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Dept Biostat, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Urol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
关键词
sexual function; brachytherapy; prostate cancer; prostatectomy; radiation therapy; quality of life; comparative effectiveness research; personalized medicine; treatment selection; toxicity; genitourinary; gastrointestinal; QUALITY-OF-LIFE; DOSE-RATE BRACHYTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; CLINICAL TARGET VOLUME; RADIATION-THERAPY; RADICAL PROSTATECTOMY; CONSENSUS GUIDELINES; AMERICAN BRACHYTHERAPY; ADVANCED TECHNOLOGY; URINARY;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: To characterize patient reported outcomes for urinary and sexual function using International Prostate Symptom Score (IPSS) and Sexual Health Inventory for Men (SHIM) comparing intensity modulated radiation therapy (IMRT), low dose rate brachytherapy (LDR), post-prostatectomy IMRT (PPRT), and radical prostatectomy (RP). Materials and methods: Patients treated for prostate cancer from 2001-2012 completed self-reported SHIM and IPSS surveys. Subgroups were created by baseline score. Mean change from baseline was determined at each time point for the cohort and subgroups. Statistical analysis was performed with generalized estimating equation method. Incontinence was not captured in the questionnaires. Results: A total of 14,523 IPSS surveys from 3,515 men were evaluated. Patients treated with IMRT experienced a minimal decrease in IPSS score from baseline. PPRT scores did not differ from IMRT at any time point (range: +1-3 points from baseline in IPSS score over 50 months). LDR had an initial IPSS rise (between 5-10 points on the IPSS over 1-9 months) versus IMRT but returned to comparable levels at 34 months. RP was associated with a lower IPSS versus IMRT. LDR had the largest rise from baseline, with return toward baseline. A total of 2,624 SHIM surveys from 857 men were evaluated. LDR and PPRT did not differ from IMRT at any time point (range: +1-5 points from baseline in SHIM score for 36 months). RP experienced the largest decline from baseline (up to -7 points on SHIM score), at 3 to 7 months; RP had a larger early decrease in SHIM score versus IMRT between 3 and 22 months, after which there was no difference. Conclusions: IPSS and SHIM score patterns differed among treatment modalities. These data can be used to predict changes in urinary and sexual function over time based on modality and baseline score.
引用
收藏
页码:8535 / 8545
页数:11
相关论文
共 50 条
  • [31] Patient activation and patient-reported outcomes of men from a community pharmacy lifestyle intervention after prostate cancer treatment
    Agnieszka Lemanska
    Karen Poole
    Ralph Manders
    John Marshall
    Zachariah Nazar
    Kevin Noble
    John M. Saxton
    Lauren Turner
    Gary Warner
    Bruce A. Griffin
    Sara Faithfull
    Supportive Care in Cancer, 2022, 30 : 347 - 358
  • [32] Patient-reported outcomes in metastatic castration-resistant prostate cancer
    Fallowfield, Lesley
    Payne, Heather
    Jenkins, Valerie
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (10) : 643 - 650
  • [33] PATIENT REPORTED OUTCOMES IN PROSTATE CANCER, A MOBILE-HEALTH ESSAY (PROPHECY)
    Fionda, Bruno
    D'Aviero, Andrea
    Alitto, Anna Rita
    Frascino, Vincenzo
    Piras, Antonio
    Catucci, Francesco
    Palazzoni, Giovanni
    Chiloiro, Giuditta
    Dinapoli, Loredana
    Lanzotti, Vito
    Valentini, Vincenzo
    Mantini, Giovanna
    ANTICANCER RESEARCH, 2019, 39 (03) : 1582 - 1583
  • [34] Using patient-reported outcomes to assess and improve prostate cancer brachytherapy
    Talcott, James A.
    Manola, Judith
    Chen, Ronald C.
    Clark, Jack A.
    Kaplan, Irving
    D'Amico, Anthony V.
    Zietman, Anthony L.
    BJU INTERNATIONAL, 2014, 114 (04) : 511 - 516
  • [35] Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
    Donovan, J. L.
    Hamdy, F. C.
    Lane, J. A.
    Mason, M.
    Metcalfe, C.
    Walsh, E.
    Blazeby, J. M.
    Peters, T. J.
    Holding, P.
    Bonnington, S.
    Lennon, T.
    Bradshaw, L.
    Cooper, D.
    Herbert, P.
    Howson, J.
    Jones, A.
    Lyons, N.
    Salter, E.
    Thompson, P.
    Tidball, S.
    Blaikie, J.
    Gray, C.
    Bollina, P.
    Catto, J.
    Doble, A.
    Doherty, A.
    Gillatt, D.
    Kockelbergh, R.
    Kynaston, H.
    Paul, A.
    Powell, P.
    Prescott, S.
    Rosario, D. J.
    Rowe, E.
    Davis, M.
    Turner, E. L.
    Martin, R. M.
    Neal, D. E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (15): : 1425 - 1437
  • [36] Patient-reported outcomes in the search for the optimal radiotherapy schedule for prostate cancer
    Rammant, E.
    Ost, P.
    Swimberghe, M.
    Vanpachtenbeke, F.
    Bultijnck, R.
    Lumen, N.
    Decaestecker, K.
    Fonteyne, V.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S246 - S247
  • [37] The Impact of Rural Residence on Patient-Reported Toxicities and Outcomes of Prostate Cancer
    Atobiloye, M. A.
    Dechet, C.
    Johnson, S. B.
    Odei, B.
    Tward, J. D.
    Suneja, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E4 - E4
  • [38] Patient-reported functional outcomes after hypofractionated radiation for prostate cancer
    NossiteR, J.
    Sujenthiran, A.
    Cowling, T.
    Parry, M.
    Charman, S.
    Cathcart, P.
    Clarke, N.
    Payne, H.
    Van der Meulen, J.
    Aggarwal, A.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S106 - S107
  • [39] Patient-reported outcomes in metastatic castration-resistant prostate cancer
    Lesley Fallowfield
    Heather Payne
    Valerie Jenkins
    Nature Reviews Clinical Oncology, 2016, 13 : 643 - 650
  • [40] Patient-reported toxicity after treatment for prostate cancer (PC)
    Hill-Kayser, Christine E.
    Vachani, Carolyn
    Hampshire, Margaret K.
    DiLullo, Gloria A.
    Metz, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)